Targeting reperfusion injury in patients with ST-segment elevation myocardial infarction: trials and tribulations.
Authors:
Journal: European heart journal
Publication Type: Journal Article
Date: 2017
DOI: PMC5381598
ID: 27118196
Chemical List
- Cardiotonic Agents|||Enzyme Inhibitors|||Mitochondrial Membrane Transport Proteins|||Mitochondrial Permeability Transition Pore|||Nitrites|||Nucleotides, Cyclic|||Oligopeptides|||Oximes|||Secosteroids|||Vasodilator Agents|||arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide|||cyclic guanosine monophosphate-adenosine monophosphate|||Nitric Oxide|||3,5-seco-4-norcholestan-5-one oxime-3-ol|||Cyclosporine|||Protein Kinase C|||Metoprolol|||Adenosine
Reference List
-
Cung TT, Morel O, Cayla G, Rioufol G, Garcia-Dorado D, Angoulvant D, Bonnefoy-Cudraz E, Guerin P, Elbaz M, Delarche N, Coste P, Vanzetto G, Metge M, Aupetit JF, Jouve B, Motreff P, Tron C, Labeque JN, Steg PG, Cottin Y, Range G, Clerc J, Claeys MJ, Coussement P, Prunier F, Moulin F, Roth O, Belle L, Dubois P, Barragan P, Gilard M, Piot C, Colin P, De PF, Morice MC, Ider O, Dubois-Rande JL, Unterseeh T, Le BH, Beard T, Blanchard D, Grollier G, Malquarti V, Staat P, Sudre A, Elmer E, Hansson MJ, Bergerot C, Boussaha I, Jossan C, Derumeaux G, Mewton N, Ovize M.
Cyclosporine before PCI in patients with acute myocardial infarction. 2015;373:1021–1031.|||
Campo G, Guastaroba P, Marzocchi A, Santarelli A, Varani E, Vignali L, Sangiorgio P, Tondi S, Serenelli C, De PR, Saia F.
Impact of COPD on long-term outcome after ST-segment elevation myocardial infarction receiving primary percutaneous coronary intervention. 2013;144:750–757.|||
Piper HM, Garcia-Dorado D, Ovize M.
A fresh look at reperfusion injury. 1998;38:291–300.|||
Yellon DM, Hausenloy DJ.
Myocardial reperfusion injury. 2007;357:1121–1135.|||
Heusch G.
Cardioprotection: chances and challenges of its translation to the clinic. 2013;381:166–175.|||
Bulluck H, Yellon DM, Hausenloy DJ.
Reducing myocardial infarct size: challenges and future opportunities. 2016;102:341–348.|||
Hausenloy DJ, Yellon DM.
Myocardial ischemia-reperfusion injury: a neglected therapeutic target. 2013;123:92–100.|||
Heusch G, Kleinbongard P, Skyschally A, Levkau B, Schulz R, Erbel R.
The coronary circulation in cardioprotection: more than just one confounder. 2012;94:237–245.|||
Ruiz-Meana M, Inserte J, Fernandez-Sanz C, Hernando V, Miro-Casas E, Barba I, Garcia-Dorado D.
The role of mitochondrial permeability transition in reperfusion-induced cardiomyocyte death depends on the duration of ischemia. 2011;106:1259–1268.|||
Barrabes JA, Inserte J, Mirabet M, Quiroga A, Hernando V, Figueras J, Garcia-Dorado D.
Antagonism of P2Y12 or GPIIb/IIIa receptors reduces platelet-mediated myocardial injury after ischaemia and reperfusion in isolated rat hearts. 2010;104:128–135.|||
Kawaguchi M, Takahashi M, Hata T, Kashima Y, Usui F, Morimoto H, Izawa A, Takahashi Y, Masumoto J, Koyama J, Hongo M, Noda T, Nakayama J, Sagara J, Taniguchi S, Ikeda U.
Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. 2011;123:594–604.|||
Sandanger O, Ranheim T, Vinge LE, Bliksoen M, Alfsnes K, Finsen AV, Dahl CP, Askevold ET, Florholmen G, Christensen G, Fitzgerald KA, Lien E, Valen G, Espevik T, Aukrust P, Yndestad A.
The NLRP3 inflammasome is up-regulated in cardiac fibroblasts and mediates myocardial ischaemia-reperfusion injury. 2013;99:164–174.|||
Hamirani YS, Wong A, Kramer CM, Salerno M.
Effect of microvascular obstruction and intramyocardial hemorrhage by CMR on LV remodeling and outcomes after myocardial infarction: a systematic review and meta-analysis. 2014;7:940–952.|||
Wu KC, Zerhouni EA, Judd RM, Lugo-Olivieri CH, Barouch LA, Schulman SP, Blumenthal RS, Lima JA.
Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. 1998;97:765–772.|||
Bouleti C, Mewton N, Germain S.
The no-reflow phenomenon: state of the art. 2015;108:661–674.|||
Atar D, Petzelbauer P, Schwitter J, Huber K, Rensing B, Kasprzak JD, Butter C, Grip L, Hansen PR, Suselbeck T, Clemmensen PM, Marin-Galiano M, Geudelin B, Buser PT.
Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial. 2009;53:720–729.|||
Armstrong PW, Granger CB, Adams PX, Hamm C, Holmes D Jr, O'Neill WW, Todaro TG, Vahanian A, Van De WF.
Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. 2007;297:43–51.|||
Ong SB, Samangouei P, Kalkhoran SB, Hausenloy DJ.
The mitochondrial permeability transition pore and its role in myocardial ischemia reperfusion injury. 2015;78C:23–34.|||
Garcia-Dorado D, Ruiz-Meana M, Inserte J, Rodriguez-Sinovas A, Piper HM.
Calcium-mediated cell death during myocardial reperfusion. 2012;94:168–180.|||
Inserte J, Hernando V, Garcia-Dorado D.
Contribution of calpains to myocardial ischaemia/reperfusion injury. 2012;96:23–31.|||
Valls-Lacalle L, Barba I, Miro-Casas E, Alburquerque-Bejar JJ, Ruiz-Meana M, Fuertes-Agudo M, Rodriguez-Sinovas A, Garcia-Dorado D.
Succinate dehydrogenase inhibition with malonate during reperfusion reduces infarct size by preventing mitochondrial permeability transition. 2016;109:374–384.|||
Inserte J, Hernando V, Vilardosa U, Abad E, Poncelas-Nozal M, Garcia-Dorado D.
Activation of cGMP/protein kinase G pathway in postconditioned myocardium depends on reduced oxidative stress and preserved endothelial nitric oxide synthase coupling. 2013;2:e005975.|||
Zhang T, Zhang Y, Cui M, Jin L, Wang Y, Lv F, Liu Y, Zheng W, Shang H, Zhang J, Zhang M, Wu H, Guo J, Zhang X, Hu X, Cao CM, Xiao RP.
CaMKII is a RIP3 substrate mediating ischemia- and oxidative stress-induced myocardial necroptosis. 2016;22:175–182.|||
Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA, Vinten-Johansen J.
Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. 2003;285:H579–H588.|||
Argaud L, Gateau-Roesch O, Raisky O, Loufouat J, Robert D, Ovize M.
Postconditioning inhibits mitochondrial permeability transition. 2005;111:194–197.|||
Skyschally A, van Caster P, Boengler K, Gres P, Musiolik J, Schilawa D, Schulz R, Heusch G.
Ischemic postconditioning in pigs: no causal role for RISK activation. 2009;104:15–18.|||
Staat P, Rioufol G, Piot C, Cottin Y, Cung TT, L'Huillier I, Aupetit JF, Bonnefoy E, Finet G, Andre-Fouet X, Ovize M.
Postconditioning the human heart. 2005;112:2143–2148.|||
Thibault H, Piot C, Staat P, Bontemps L, Sportouch C, Rioufol G, Cung TT, Bonnefoy E, Angoulvant D, Aupetit JF, Finet G, Andre-Fouet X, Macia JC, Raczka F, Rossi R, Itti R, Kirkorian G, Derumeaux G, Ovize M.
Long-term benefit of postconditioning. 2008;117:1037–1044.|||
Roubille F, Mewton N, Elbaz M, Roth O, Prunier F, Cung TT, Piot C, Roncalli J, Rioufol G, Bonnefoy-Cudraz E, Wiedemann JY, Furber A, Jacquemin L, Willoteaux S, Abi-Khallil W, Sanchez I, Finet G, Sibellas F, Ranc S, Boussaha I, Croisille P, Ovize M.
No post-conditioning in the human heart with thrombolysis in myocardial infarction flow 2-3 on admission. 2014;35:1675–1682.|||
Lonborg J, Kelbaek H, Vejlstrup N, Jorgensen E, Helqvist S, Saunamaki K, Clemmensen P, Holmvang L, Treiman M, Jensen JS, Engstrom T.
Cardioprotective effects of ischemic postconditioning in patients treated with primary percutaneous coronary intervention, evaluated by magnetic resonance. 2010;3:34–41.|||
Freixa X, Bellera N, Ortiz-Perez JT, Jimenez M, Pare C, Bosch X, De Caralt TM, Betriu A, Masotti M.
Ischaemic postconditioning revisited: lack of effects on infarct size following primary percutaneous coronary intervention. 2012;33:103–112.|||
Hahn JY, Song YB, Kim EK, Yu CW, Bae JW, Chung WY, Choi SH, Choi JH, Bae JH, An KJ, Park JS, Oh JH, Kim SW, Hwang JY, Ryu JK, Park HS, Lim DS, Gwon HC.
Ischemic postconditioning during primary percutaneous coronary intervention: the effects of postconditioning on myocardial reperfusion in patients with ST-segment elevation myocardial infarction (POST) randomized trial. 2013;128:1889–1896.|||
Heusch G.
Reduction of infarct size by ischaemic post-conditioning in humans: fact or fiction? 2012;33:13–15.|||
Ovize M, Baxter GF, Di Lisa F, Ferdinandy P, Garcia-Dorado D, Hausenloy DJ, Heusch G, Vinten-Johansen J, Yellon DM, Schulz R.
Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. 2010;87:406–423.|||
Hausenloy DJ, Baxter G, Bell R, Botker HE, Davidson SM, Downey J, Heusch G, Kitakaze M, Lecour S, Mentzer R, Mocanu MM, Ovize M, Schulz R, Shannon R, Walker M, Walkinshaw G, Yellon DM.
Translating novel strategies for cardioprotection: the Hatter Workshop Recommendations. 2010;105:677–686.|||
Hausenloy DJ, Erik BH, Condorelli G, Ferdinandy P, Garcia-Dorado D, Heusch G, Lecour S, van Laake LW, Madonna R, Ruiz-Meana M, Schulz R, Sluijter JP, Yellon DM, Ovize M.
Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. 2013;98:7–27.|||
Ibanez B, Heusch G, Ovize M, Van de Werf F.
Evolving therapies for myocardial ischemia/reperfusion injury. 2015;65:1454–1471.|||
Ferdinandy P, Hausenloy DJ, Heusch G, Baxter GF, Schulz R.
Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning. 2014;66:1142–1174.|||
Hofsten DE, Kelbaek H, Helqvist S, Klovgaard L, Holmvang L, Clemmensen P, Torp-Pedersen C, Tilsted HH, Botker HE, Jensen LO, Kober L, Engstrom T.
The third DANish study of optimal acute treatment of patients with ST-segment elevation myocardial infarction: ischemic postconditioning or deferred stent implantation versus conventional primary angioplasty and complete revascularization versus treatment of culprit lesion only: rationale and design of the DANAMI 3 trial program. 2015;169:613–621.|||
Przyklenk K, Bauer B, Ovize M, Kloner RA, Whittaker P.
Regional ischemic ‘preconditioning’ protects remote virgin myocardium from subsequent sustained coronary occlusion. 1993;87:893–899.|||
Birnbaum Y, Hale SL, Kloner RA.
Ischemic preconditioning at a distance: reduction of myocardial infarct size by partial reduction of blood supply combined with rapid stimulation of the gastrocnemius muscle in the rabbit. 1997;96:1641–1646.|||
Hausenloy DJ, Yellon DM.
Remote ischaemic preconditioning: underlying mechanisms and clinical application. 2008;79:377–386.|||
Sivaraman V, Pickard JM, Hausenloy DJ.
Remote ischaemic conditioning: cardiac protection from afar. 2015;70:732–748.|||
Heusch G, Botker HE, Przyklenk K, Redington A, Yellon D.
Remote ischemic conditioning. 2015;65:177–195.|||
Hausenloy DJ, Mwamure PK, Venugopal V, Harris J, Barnard M, Grundy E, Ashley E, Vichare S, Di Salvo C, Kolvekar S, Hayward M, Keogh B, MacAllister RJ, Yellon DM.
Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomised controlled trial. 2007;370:575–579.|||
Thielmann M, Kottenberg E, Boengler K, Raffelsieper C, Neuhaeuser M, Peters J, Jakob H, Heusch G.
Remote ischemic preconditioning reduces myocardial injury after coronary artery bypass surgery with crystalloid cardioplegic arrest. 2010;105:657–664.|||
Hausenloy DJ, Candilio L, Evans R, Ariti C, Jenkins DP, Kolvekar S, Knight R, Kunst G, Laing C, Nicholas J, Pepper J, Robertson S, Xenou M, Clayton T, Yellon DM.
Remote ischemic preconditioning and outcomes of cardiac surgery. 2015;373:1408–1417.|||
Meybohm P, Bein B, Brosteanu O, Cremer J, Gruenewald M, Stoppe C, Coburn M, Schaelte G, Boning A, Niemann B, Roesner J, Kletzin F, Strouhal U, Reyher C, Laufenberg-Feldmann R, Ferner M, Brandes IF, Bauer M, Stehr SN, Kortgen A, Wittmann M, Baumgarten G, Meyer-Treschan T, Kienbaum P, Heringlake M, Schon J, Sander M, Treskatsch S, Smul T, Wolwender E, Schilling T, Fuernau G, Hasenclever D, Zacharowski K.
A multicenter trial of remote ischemic preconditioning for heart surgery. 2015;373:1397–1407.|||
Thielmann M, Kottenberg E, Kleinbongard P, Wendt D, Gedik N, Pasa S, Price V, Tsagakis K, Neuhauser M, Peters J, Jakob H, Heusch G.
Cardioprotective and prognostic effects of remote ischaemic preconditioning in patients undergoing coronary artery bypass surgery: a single-centre randomised, double-blind, controlled trial. 2013;382:597–604.|||
Botker HE, Kharbanda R, Schmidt MR, Bottcher M, Kaltoft AK, Terkelsen CJ, Munk K, Andersen NH, Hansen TM, Trautner S, Lassen JF, Christiansen EH, Krusell LR, Kristensen SD, Thuesen L, Nielsen SS, Rehling M, Sorensen HT, Redington AN, Nielsen TT.
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. 2010;375:727–734.|||
Crimi G, Pica S, Raineri C, Bramucci E, De Ferrari GM, Klersy C, Ferlini M, Marinoni B, Repetto A, Romeo M, Rosti V, Massa M, Raisaro A, Leonardi S, Rubartelli P, Oltrona VL, Ferrario M.
Remote ischemic post-conditioning of the lower limb during primary percutaneous coronary intervention safely reduces enzymatic infarct size in anterior myocardial infarction: a randomized controlled trial. 2013;6:1055–1063.|||
Prunier F, Angoulvant D, Saint EC, Vermes E, Gilard M, Piot C, Roubille F, Elbaz M, Ovize M, Biere L, Jeanneteau J, Delepine S, Benard T, Abi-Khalil W, Furber A.
The RIPOST-MI study, assessing remote ischemic perconditioning alone or in combination with local ischemic postconditioning in ST-segment elevation myocardial infarction. 2014;109:400.|||
White SK, Frohlich GM, Sado DM, Maestrini V, Fontana M, Treibel TA, Tehrani S, Flett AS, Meier P, Ariti C, Davies JR, Moon JC, Yellon DM, Hausenloy DJ.
Remote ischemic conditioning reduces myocardial infarct size and edema in patients with ST-segment elevation myocardial infarction. 2015;8(Pt B):178–188.|||
Eitel I, Stiermaier T, Rommel KP, Fuernau G, Sandri M, Mangner N, Linke A, Erbs S, Lurz P, Boudriot E, Mende M, Desch S, Schuler G, Thiele H.
Cardioprotection by combined intrahospital remote ischaemic perconditioning and postconditioning in ST-elevation myocardial infarction: the randomized LIPSIA CONDITIONING trial. 2015;36:3049–3057.|||
Yellon DM, Ackbarkhan AK, Balgobin V, Bulluck H, Deelchand A, Dhuny MR, Domah N, Gaoneadry D, Jagessur RK, Joonas N, Kowlessur S, Lutchoo J, Nicholas JM, Pauvaday K, Shamloll O, Walker JM, Hausenloy DJ.
Remote ischemic conditioning reduces myocardial infarct size in STEMI patients treated by thrombolysis. 2015;65:2764–2765.|||
Munk K, Andersen NH, Schmidt MR, Nielsen SS, Terkelsen CJ, Sloth E, Botker HE, Nielsen TT, Poulsen SH.
Remote ischemic conditioning in patients with myocardial infarction treated with primary angioplasty: impact on left ventricular function assessed by comprehensive echocardiography and gated single-photon emission CT. 2010;3:656–662.|||
Sloth AD, Schmidt MR, Munk K, Kharbanda RK, Redington AN, Schmidt M, Pedersen L, Sorensen HT, Botker HE.
Improved long-term clinical outcomes in patients with ST-elevation myocardial infarction undergoing remote ischaemic conditioning as an adjunct to primary percutaneous coronary intervention. 2014;35:168–175.|||
Sloth AD, Schmidt MR, Munk K, Schmidt M, Pedersen L, Sorensen HT, Botker HE.
Impact of cardiovascular risk factors and medication use on the efficacy of remote ischaemic conditioning: post hoc subgroup analysis of a randomised controlled trial. 2015;5:e006923.|||
Hausenloy DJ, Kharbanda R, Rahbek SM, Moller UK, Ravkilde J, Okkels JL, Engstrom T, Garcia Ruiz JM, Radovanovic N, Christensen EF, Sorensen HT, Ramlall M, Bulluck H, Evans R, Nicholas J, Knight R, Clayton T, Yellon DM, Botker HE.
Effect of remote ischaemic conditioning on clinical outcomes in patients presenting with an ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. 2015;36:1846–1848.|||
Padilla F, Garcia-Dorado D, Agullo L, Barrabes JA, Inserte J, Escalona N, Meyer M, Mirabet M, Pina P, Soler-Soler J.
Intravenous administration of the natriuretic peptide urodilatin at low doses during coronary reperfusion limits infarct size in anesthetized pigs. 2001;51:592–600.|||
Kitakaze M, Asakura M, Kim J, Shintani Y, Asanuma H, Hamasaki T, Seguchi O, Myoishi M, Minamino T, Ohara T, Nagai Y, Nanto S, Watanabe K, Fukuzawa S, Hirayama A, Nakamura N, Kimura K, Fujii K, Ishihara M, Saito Y, Tomoike H, Kitamura S.
Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. 2007;370:1483–1493.|||
Selker HP, Beshansky JR, Sheehan PR, Massaro JM, Griffith JL, D'Agostino RB, Ruthazer R, Atkins JM, Sayah AJ, Levy MK, Richards ME, Aufderheide TP, Braude DA, Pirrallo RG, Doyle DD, Frascone RJ, Kosiak DJ, Leaming JM, Van Gelder CM, Walter GP, Wayne MA, Woolard RH, Opie LH, Rackley CE, Apstein CS, Udelson JE.
Out-of-hospital administration of intravenous glucose-insulin-potassium in patients with suspected acute coronary syndromes: the IMMEDIATE randomized controlled trial. 2012;307:1925–1933.|||
Hausenloy DJ, Yellon DM.
GLP-1 therapy: beyond glucose control. 2008;1:147–149.|||
Sonne DP, Engstrom T, Treiman M.
Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. 2008;146:243–249.|||
Timmers L, Henriques JP, de Kleijn DP, Devries JH, Kemperman H, Steendijk P, Verlaan CW, Kerver M, Piek JJ, Doevendans PA, Pasterkamp G, Hoefer IE.
Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. 2009;53:501–510.|||
Lonborg J, Vejlstrup N, Kelbaek H, Botker HE, Kim WY, Mathiasen AB, Jorgensen E, Helqvist S, Saunamaki K, Clemmensen P, Holmvang L, Thuesen L, Krusell LR, Jensen JS, Kober L, Treiman M, Holst JJ, Engstrom T.
Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. 2012;33:1491–1499.|||
Lonborg J, Kelbaek H, Vejlstrup N, Botker HE, Kim WY, Holmvang L, Jorgensen E, Helqvist S, Saunamaki K, Terkelsen CJ, Schoos MM, Kober L, Clemmensen P, Treiman M, Engstrom T.
Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia. 2012;5:288–295.|||
Woo JS, Kim W, Ha SJ, Kim JB, Kim SJ, Kim WS, Seon HJ, Kim KS.
Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study. 2013;33:2252–2260.|||
Chen WR, Hu SY, Chen YD, Zhang Y, Qian G, Wang J, Yang JJ, Wang ZF, Tian F, Ning QX.
Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. 2015;170:845–854.|||
Heusch G.
Molecular basis of cardioprotection: signal transduction in ischemic pre-, post-, and remote conditioning. 2015;116:674–699.|||
Rassaf T, Totzeck M, Hendgen-Cotta UB, Shiva S, Heusch G, Kelm M.
Circulating nitrite contributes to cardioprotection by remote ischemic preconditioning. 2014;114:1601–1610.|||
Duranski MR, Greer JJ, Dejam A, Jaganmohan S, Hogg N, Langston W, Patel RP, Yet SF, Wang X, Kevil CG, Gladwin MT, Lefer DJ.
Cytoprotective effects of nitrite during in vivo ischemia-reperfusion of the heart and liver. 2005;115:1232–1240.|||
Lefer DJ, Bolli R.
Development of an NIH consortium for preclinicAl AssESsment of CARdioprotective therapies (CAESAR): a paradigm shift in studies of infarct size limitation. 2011;16:332–339.|||
Lefer D, Jones S, Steenbergen C, Kukreja R, Guo Y, Tang X-L, Li Q, Ockaili R, Salloum F, Kong M, Polhemus D, Bhushan S, Goodchild T, Chang C, Book M, Du J, Bolli R.
Sodium nitrite fails to limit myocardial infarct size: results from the CAESAR cardioprotection consortium. 2014;28:LB645.|||
Siddiqi N, Neil C, Bruce M, MacLennan G, Cotton S, Papadopoulou S, Feelisch M, Bunce N, Lim PO, Hildick-Smith D, Horowitz J, Madhani M, Boon N, Dawson D, Kaski JC, Frenneaux M.
Intravenous sodium nitrite in acute ST-elevation myocardial infarction: a randomized controlled trial (NIAMI). 2014;35:1255–1262.|||
Jones DA, Pellaton C, Velmurugan S, Rathod KS, Andiapen M, Antoniou S, van ES, Webb AJ, Westwood MA, Parmar MK, Mathur A, Ahluwalia A.
Randomized phase 2 trial of intracoronary nitrite during acute myocardial infarction. 2015;116:437–447.|||
Hausenloy DJ, Maddock HL, Baxter GF, Yellon DM.
Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning? 2002;55:534–543.|||
Argaud L, Gateau-Roesch O, Muntean D, Chalabreysse L, Loufouat J, Robert D, Ovize M.
Specific inhibition of the mitochondrial permeability transition prevents lethal reperfusion injury. 2005;38:367–374.|||
Skyschally A, Schulz R, Heusch G.
Cyclosporine A at reperfusion reduces infarct size in pigs. 2010;24:85–87.|||
Karlsson LO, Zhou AX, Larsson E, Astrom-Olsson K, Mansson C, Akyurek LM, Grip L.
Cyclosporine does not reduce myocardial infarct size in a porcine ischemia-reperfusion model. 2010;15:182–189.|||
Lim WY, Messow CM, Berry C.
Cyclosporin variably and inconsistently reduces infarct size in experimental models of reperfused myocardial infarction: a systematic review and meta-analysis. 2012;165:2034–2043.|||
Piot C, Croisille P, Staat P, Thibault H, Rioufol G, Mewton N, Elbelghiti R, Cung TT, Bonnefoy E, Angoulvant D, Macia C, Raczka F, Sportouch C, Gahide G, Finet G, Andre-Fouet X, Revel D, Kirkorian G, Monassier JP, Derumeaux G, Ovize M.
Effect of cyclosporine on reperfusion injury in acute myocardial infarction. 2008;359:473–481.|||
Ghaffari S, Kazemi B, Toluey M, Sepehrvand N.
The effect of prethrombolytic cyclosporine-A injection on clinical outcome of acute anterior ST-elevation myocardial infarction. 2013;31:e34–e39.|||
Chiari P, Angoulvant D, Mewton N, Desebbe O, Obadia JF, Robin J, Farhat F, Jegaden O, Bastien O, Lehot JJ, Ovize M.
Cyclosporine protects the heart during aortic valve surgery. 2014;121:232–238.|||
Hausenloy D, Kunst G, Boston-Griffiths E, Kolvekar S, Chaubey S, John L, Desai J, Yellon D.
The effect of cyclosporin-A on peri-operative myocardial injury in adult patients undergoing coronary artery bypass graft surgery: a randomised controlled clinical trial. 2014;100:544–549.|||
Nighoghossian N, Berthezene Y, Mechtouff L, Derex L, Cho TH, Ritzenthaler T, Rheims S, Chauveau F, Bejot Y, Jacquin A, Giroud M, Ricolfi F, Philippeau F, Lamy C, Turc G, Bodiguel E, Domigo V, Guiraud V, Mas JL, Oppenheim C, Amarenco P, Cakmak S, Sevin-Allouet M, Guillon B, Desal H, Hosseini H, Sibon I, Mahagne MH, Ong E, Mewton N, Ovize M.
Cyclosporine in acute ischemic stroke. 2015;84:2216–2223.|||
Latini R, Limbruno U, La Vecchia L, Locuratolo N, Costalunga A, Sixuro M, Lombardi M, Staszewsky L, Masson S, Milani V, Barlera S, Maggioni AP, Ottani F.
Effect of cyclosporine a on infarct size reduction in reperfused acute myocardial infarction treated with primary angioplasty. 2014;130:A15211.|||
Hausenloy DJ, Yellon DM.
Targeting myocardial reperfusion injury—the search continues. 2015;373:1073–1075.|||
Heusch G.
CIRCUS: a kiss of death for cardioprotection? 2015;108:215–216.|||
Hausenloy DJ, Boston-Griffiths EA, Yellon DM.
Cyclosporin A and cardioprotection: from investigative tool to therapeutic agent. 2012;165:1235–1245.|||
Yang XM, Liu Y, Cui L, Yang X, Liu Y, Tandon N, Kambayashi J, Downey JM, Cohen MV.
Platelet P2Y(1)(2) blockers confer direct postconditioning-like protection in reperfused rabbit hearts. 2013;18:251–262.|||
Dai W, Shi J, Gupta RC, Sabbah HN, Hale SL, Kloner RA.
Bendavia, a mitochondria-targeting peptide, improves postinfarction cardiac function, prevents adverse left ventricular remodeling, and restores mitochondria-related gene expression in rats. 2014;64:543–553.|||
Shi J, Dai W, Hale SL, Brown DA, Wang M, Han X, Kloner RA.
Bendavia restores mitochondrial energy metabolism gene expression and suppresses cardiac fibrosis in the border zone of the infarcted heart. 2015;141:170–178.|||
Gibson CM, Giugliano RP, Kloner RA, Bode C, Tendera M, Janosi A, Merkely B, Godlewski J, Halaby R, Korjian S, Daaboul Y, Chakrabarti AK, Spielman K, Neal BJ, Weaver WD.
EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention. 2015;doi.org/10.1093/eurheartj/ehv597.|||
Schaller S, Paradis S, Ngoh GA, Assaly R, Buisson B, Drouot C, Ostuni MA, Lacapere JJ, Bassissi F, Bordet T, Berdeaux A, Jones SP, Morin D, Pruss RM.
TRO40303, a new cardioprotective compound, inhibits mitochondrial permeability transition. 2010;333:696–706.|||
Hansson MJ, Llwyd O, Morin D, De PD, Arnoux T, Gouarne C, Koul S, Engblom H, Bordet T, Tissier R, Arheden H, Erlinge D, Halestrap AP, Berdeaux A, Pruss RM, Schaller S.
Differences in the profile of protection afforded by TRO40303 and mild hypothermia in models of cardiac ischemia/reperfusion injury. 2015;760:7–19.|||
Atar D, Arheden H, Berdeaux A, Bonnet JL, Carlsson M, Clemmensen P, Cuvier V, Danchin N, Dubois-Rande JL, Engblom H, Erlinge D, Firat H, Halvorsen S, Hansen HS, Hauke W, Heiberg E, Koul S, Larsen AI, Le CP, Nordrehaug JE, Paganelli F, Pruss RM, Rousseau H, Schaller S, Sonou G, Tuseth V, Veys J, Vicaut E, Jensen SE.
Effect of intravenous TRO40303 as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: MITOCARE study results. 2015;36:112–119.|||
Chen L, Hahn H, Wu G, Chen CH, Liron T, Schechtman D, Cavallaro G, Banci L, Guo Y, Bolli R, Dorn GW, Mochly-Rosen D.
Opposing cardioprotective actions and parallel hypertrophic effects of delta PKC and epsilon PKC. 2001;98:11114–11119.|||
Inagaki K, Chen L, Ikeno F, Lee FH, Imahashi K, Bouley DM, Rezaee M, Yock PG, Murphy E, Mochly-Rosen D.
Inhibition of delta-protein kinase C protects against reperfusion injury of the ischemic heart in vivo. 2003;108:2304–2307.|||
Fryer RM, Wang Y, Hsu AK, Gross GJ.
Essential activation of PKC-delta in opioid-initiated cardioprotection. 2001;280:H1346–H1353.|||
Mayr M, Metzler B, Chung YL, McGregor E, Mayr U, Troy H, Hu Y, Leitges M, Pachinger O, Griffiths JR, Dunn MJ, Xu Q.
Ischemic preconditioning exaggerates cardiac damage in PKC-delta null mice. 2004;287:H946–H956.|||
Bates E, Bode C, Costa M, Gibson CM, Granger C, Green C, Grimes K, Harrington R, Huber K, Kleiman N, Mochly-Rosen D, Roe M, Sadowski Z, Solomon S, Widimsky P.
Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. 2008;117:886–896.|||
Lincoff AM, Roe M, Aylward P, Galla J, Rynkiewicz A, Guetta V, Zelizko M, Kleiman N, White H, McErlean E, Erlinge D, Laine M, Dos Santos Ferreira JM, Goodman S, Mehta S, Atar D, Suryapranata H, Jensen SE, Forster T, Fernandez-Ortiz A, Schoors D, Radke P, Belli G, Brennan D, Bell G, Krucoff M.
Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI randomized controlled trial. 2014;35:2516–2523.|||
Olafsson B, Forman MB, Puett DW, Pou A, Cates CU, Friesinger GC, Virmani R.
Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: importance of the endothelium and the no-reflow phenomenon. 1987;76:1135–1145.|||
Goto M, Miura T, Iliodoromitis EK, O'Leary EL, Ishimoto R, Yellon DM, Iimura O.
Adenosine infusion during early reperfusion failed to limit myocardial infarct size in a collateral deficient species. 1991;25:943–949.|||
Bulluck H, Sirker A, Loke YK, Garcia-Dorado D, Hausenloy DJ.
Clinical benefit of adenosine as an adjunct to reperfusion in ST-elevation myocardial infarction patients: an updated meta-analysis of randomized controlled trials. 2015;202:228–237.|||
Mahaffey KW, Puma JA, Barbagelata NA, DiCarli MF, Leesar MA, Browne KF, Eisenberg PR, Bolli R, Casas AC, Molina-Viamonte V, Orlandi C, Blevins R, Gibbons RJ, Califf RM, Granger CB.
Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. 1999;34:1711–1720.|||
Ross AM, Gibbons RJ, Stone GW, Kloner RA, Alexander RW.
A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). 2005;45:1775–1780.|||
Kloner RA, Forman MB, Gibbons RJ, Ross AM, Alexander RW, Stone GW.
Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial. 2006;27:2400–2405.|||
Garcia-Dorado D, Garcia-del-Blanco B, Otaegui I, Rodriguez-Palomares J, Pineda V, Gimeno F, Ruiz-Salmeron R, Elizaga J, Evangelista A, Fernandez-Aviles F, San-Roman A, Ferreira-Gonzalez I.
Intracoronary injection of adenosine before reperfusion in patients with ST-segment elevation myocardial infarction: a randomized controlled clinical trial. 2014;177:935–941.|||
Herring MJ, Hale SL, Dai W, Oskui PM, Kloner RA.
Hypothermia in the setting of experimental acute myocardial infarction: a comprehensive review. 2014;4:159–167.|||
Duncker DJ, Klassen CL, Ishibashi Y, Herrlinger SH, Pavek TJ, Bache RJ.
Effect of temperature on myocardial infarction in swine. 1996;270(Pt 2):H1189–H1199.|||
Dae MW, Gao DW, Sessler DI, Chair K, Stillson CA.
Effect of endovascular cooling on myocardial temperature, infarct size, and cardiac output in human-sized pigs. 2002;282:H1584–H1591.|||
Gotberg M, Olivecrona GK, Engblom H, Ugander M, van der Pals J, Heiberg E, Arheden H, Erlinge D.
Rapid short-duration hypothermia with cold saline and endovascular cooling before reperfusion reduces microvascular obstruction and myocardial infarct size. 2008;8:7.|||
Maeng M, Mortensen UM, Kristensen J, Kristiansen SB, Andersen HR.
Hypothermia during reperfusion does not reduce myocardial infarct size in pigs. 2006;101:61–68.|||
Gotberg M, van der Pals J, Gotberg M, Olivecrona GK, Kanski M, Koul S, Otto A, Engblom H, Ugander M, Arheden H, Erlinge D.
Optimal timing of hypothermia in relation to myocardial reperfusion. 2011;106:697–708.|||Grines CL. Intravascular cooling adjunctive to percutaneous coronary intervention (part 1). Presentation at Transcatheter Cardiovascular Therapeutics, September 2004, Washington DC, USA.|||
O'Neill WW, Dixon SR, Grines CL.
The year in interventional cardiology. 2005;45:1117–1134.|||
Gotberg M, Olivecrona GK, Koul S, Carlsson M, Engblom H, Ugander M, van der Pals J, Algotsson L, Arheden H, Erlinge D.
A pilot study of rapid cooling by cold saline and endovascular cooling before reperfusion in patients with ST-elevation myocardial infarction. 2010;3:400–407.|||
Erlinge D, Gotberg M, Lang I, Holzer M, Noc M, Clemmensen P, Jensen U, Metzler B, James S, Botker HE, Omerovic E, Engblom H, Carlsson M, Arheden H, Ostlund O, Wallentin L, Harnek J, Olivecrona GK.
Rapid endovascular catheter core cooling combined with cold saline as an adjunct to percutaneous coronary intervention for the treatment of acute myocardial infarction. The CHILL-MI trial: a randomized controlled study of the use of central venous catheter core cooling combined with cold saline as an adjunct to percutaneous coronary intervention for the treatment of acute myocardial infarction. 2014;63:1857–1865.|||
Herring MJ, Dai W, Hale SL, Kloner RA.
Rapid induction of hypothermia by the thermosuit system profoundly reduces infarct size and anatomic zone of no reflow following ischemia-reperfusion in rabbit and rat hearts. 2015;20:193–202.|||
Ibanez B, Prat-Gonzalez S, Speidl WS, Vilahur G, Pinero A, Cimmino G, Garcia MJ, Fuster V, Sanz J, Badimon JJ.
Early metoprolol administration before coronary reperfusion results in increased myocardial salvage: analysis of ischemic myocardium at risk using cardiac magnetic resonance. 2007;115:2909–2916.|||
Ibanez B, Macaya C, Sanchez-Brunete V, Pizarro G, Fernandez-Friera L, Mateos A, Fernandez-Ortiz A, Garcia-Ruiz JM, Garcia-Alvarez A, Iniguez A, Jimenez-Borreguero J, Lopez-Romero P, Fernandez-Jimenez R, Goicolea J, Ruiz-Mateos B, Bastante T, Arias M, Iglesias-Vazquez JA, Rodriguez MD, Escalera N, Acebal C, Cabrera JA, Valenciano J, Perez de PA, Fernandez-Campos MJ, Casado I, Garcia-Rubira JC, Garcia-Prieto J, Sanz-Rosa D, Cuellas C, Hernandez-Antolin R, Albarran A, Fernandez-Vazquez F, de la Torre-Hernandez JM, Pocock S, Sanz G, Fuster V.
Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the effect of metoprolol in cardioprotection during an acute myocardial infarction (METOCARD-CNIC) trial. 2013;128:1495–1503.|||
Pizarro G, Fernandez-Friera L, Fuster V, Fernandez-Jimenez R, Garcia-Ruiz JM, Garcia-Alvarez A, Mateos A, Barreiro MV, Escalera N, Rodriguez MD, de MA, Garcia-Lunar I, Parra-Fuertes JJ, Sanchez-Gonzalez J, Pardillos L, Nieto B, Jimenez A, Abejon R, Bastante T, Martinez dV V, Cabrera JA, Lopez-Melgar B, Guzman G, Garcia-Prieto J, Mirelis JG, Zamorano JL, Albarran A, Goicolea J, Escaned J, Pocock S, Iniguez A, Fernandez-Ortiz A, Sanchez-Brunete V, Macaya C, Ibanez B.
Long-term benefit of early pre-reperfusion metoprolol administration in patients with acute myocardial infarction: results from the METOCARD-CNIC trial (Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction). 2014;63:2356–2362.|||
Roolvink V, Rasoul S, Ottervanger JP, Dambrink JH, Lipsic E, van der Horst IC, Bart de SB, Kedhi E, Marcel Gosselink AT, Piek JJ, Sanchez-Brunete V, Ibanez B, Fuster V, Van't Hof AW.
Rationale and design of a double-blind, multicenter, randomized, placebo-controlled clinical trial of early administration of intravenous beta-blockers in patients with ST-elevation myocardial infarction before primary percutaneous coronary intervention: EARLY beta-blocker administration before primary PCI in patients with ST-elevation myocardial infarction trial. 2014;168:661–666.|||
Lecour S, Botker HE, Condorelli G, Davidson SM, Garcia-Dorado D, Engel FB, Ferdinandy P, Heusch G, Madonna R, Ovize M, Ruiz-Meana M, Schulz R, Sluijter JP, van Laake LW, Yellon DM, Hausenloy DJ.
ESC working group cellular biology of the heart: position paper: improving the preclinical assessment of novel cardioprotective therapies. 2014;104:399–411.|||
Roubille F, Lairez O, Mewton N, Rioufol G, Ranc S, Sanchez I, Cung TT, Elbaz M, Piot C, Ovize M.
Cardioprotection by clopidogrel in acute ST-elevated myocardial infarction patients: a retrospective analysis. 2012;107:275.|||
Kloner RA, Schwartz LL.
State of the Science of Cardioprotection: challenges and opportunities—proceedings of the 2010 NHLBI workshop on cardioprotection. 2011;16:223–232.|||
Sorensson P, Saleh N, Bouvier F, Bohm F, Settergren M, Caidahl K, Tornvall P, Arheden H, Ryden L, Pernow J.
Effect of postconditioning on infarct size in patients with ST elevation myocardial infarction. 2010;96:1710–1715.|||
Alburquerque-Bejar JJ, Barba I, Inserte J, Miro-Casas E, Ruiz-Meana M, Poncelas M, Vilardosa U, Valls-Lacalle L, Rodriguez-Sinovas A, Garcia-Dorado D.
Combination therapy with remote ischaemic conditioning and insulin or exenatide enhances infarct size limitation in pigs. 2015;107:246–254.